Unbalanced Vitreous Levels of Osteoprotegerin, RANKL, RANK, and TRAIL in Proliferative Diabetic Retinopathy

References

• Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653–660.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–364.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Nawaz MI, De Hertogh G, et al. S100A4 is upregulated in proliferative diabetic retinopathy and correlates with markers of angiogenesis and fibrogenesis. Mol Vis. 2014;20:1209–1224.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Nawaz MI, Kangave D, et al. Angiogenic and vasculogenic factors in the vitreous from patients with proliferative diabetic retinopathy. J Diabetes Res. 2013;2013:539658.
   PubMed Web of Science ®Google Scholar
• El-Asrar AM, Nawaz MI, Kangave D, et al. High-mobility group box-1and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy. Mol Vis. 2011;17:1829–1838.
   PubMed Web of Science ®Google Scholar
• Nawaz MI, Van Raemdonck K, Mohammad G, et al. Autocrine CCL2, CXCL4, CXCL9 and CXCL10 signal in retinal endothelial cells and are enhanced in diabetic retinopathy. Exp Eye Res. 2013;109:67–76.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Mohammad G, Nawaz MI, et al. Relationship between vitreous levels of matrix metalloproteinases and vascular endothelial growth factor in proliferative diabetic retinopathy. PLoS One. 2013;8(12):e85857.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Alam K, Nawaz MI, et al. Upregulated expression of heparanase in the vitreous of patients with proliferative diabetic retinopathy originates from activated endothelial cells and leukocytes. Invest Ophthalmol Vis Sci. 2015;56:8239–8247.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Siddiquei MM, Nawaz MI, et al. Coexpression of heparanase activity, cathepsin L, tissue factor, tissue factor pathway inhibitor, and MMP-9 in proliferative diabetic retinopathy. Mol Vis. 2016;22:424–435.
   PubMed Web of Science ®Google Scholar
• Spranger J, Pfeiffer AF. New concepts in pathogenesis and treatment of diabetic retinopathy. Exp Clin Endocrinol Diabetes. 2001;109(Suppl 2):S438–S450.
   PubMedGoogle Scholar
• Dorrell MI, Aguilar E, Scheppke L, et al. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci USA. 2007;104:967–972.
   PubMed Web of Science ®Google Scholar
• Salam A, Mathew R, Sivaprasad S. Treatment of proliferative diabetic retinopathy with anti-VEGF agents. Acta Ophthalmol. 2011;89:405–411.
   PubMed Web of Science ®Google Scholar
• McGonigle JS, Giachelli CM, Scatena M. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis. 2009;12:35–46.
   PubMed Web of Science ®Google Scholar
• Na HJ, Hwang JY, Lee KS, et al. TRAIL negatively regulates VEGF-induced angiogenesis via caspase-8-mediated enzymatic and non-enzymatic functions. Angiogenesis. 2014;17:179–194.
   PubMed Web of Science ®Google Scholar
• Chen PL, Easton AS. Evidence that tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits angiogenesis by inducing vascular endothelial cell apoptosis. Biochem Biophys Res Commun. 2010;391:936–941.
   PubMed Web of Science ®Google Scholar
• Cantarella G, Risuglia N, Dell’eva R, et al. TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells. Br J Cancer. 2006;94:142814–142835.
   Web of Science ®Google Scholar
• Reid P, Holen I. Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol. 2009;88:1–17.
   PubMed Web of Science ®Google Scholar
• Zauli G, Melloni E, Capitani S, et al. Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci. 2009;66:841–851.
   PubMed Web of Science ®Google Scholar
• Cross SS, Yang Z, Brown NJ, et al. Osteoprotegenerin (OPG) – a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer. 2006;118:1901–1908.
   PubMed Web of Science ®Google Scholar
• Renema N, Navet B, Heymann MF, et al. RANK-RANKL signalling in cancer. Biosci Rep. 2016;36:e00366.
   PubMed Web of Science ®Google Scholar
• Vitovski S, Phillips JS, Sayers J, et al. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: Evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem. 2007;282:31601–31609.
   PubMed Web of Science ®Google Scholar
• Nelson CA, Warren JT, Wang MW, et al. RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure. 2012;20:1971–1982.
   PubMed Web of Science ®Google Scholar
• Yu G, Ji X, Jin J, et al. Association of serum and vitreous concentrations of osteoprotegerin with diabetic retinopathy. Ann Clin Biochem. 2015;52(Pt 2):232–236.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Struyf S, Mohammad G, et al. Osteoprotegerin is a new regulator of inflammation and angiogenesis in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2017;58:3189–3201.
   PubMed Web of Science ®Google Scholar
• Goswami S, Sharma-Walia N. Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis. BMC Cancer. 2015;15:935.
   PubMed Web of Science ®Google Scholar
• Reid PE, Brown NJ, Holen I. Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact. Mol Cancer. 2009;8:49.
   PubMed Web of Science ®Google Scholar
• Kobayashi-Sakamoto M, Isogai E, Holen I. Osteoprotegerin induces cytoskeletal reorganization and activates FAK, Src, and ERK signaling in endothelial cells. Eur J Haematol. 2010;85:26–35.
   PubMed Web of Science ®Google Scholar
• Malyankar UM, Scatena M, Suchland KL, et al. Osteoprotegerin is an αvβ3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem. 2000;275:20959–20962.
   PubMed Web of Science ®Google Scholar
• Pritzker LB, Scatena M, Giachelli CM. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell. 2004;15:2834–2841.
   PubMed Web of Science ®Google Scholar
• Nahidi L, Leach ST, Lemberg DA, et al. Osteoprotegerin exerts its pro-inflammatory effects through nuclear factor-κB activation. Dig Dis Sci. 2013;58:3144–3155.
   PubMed Web of Science ®Google Scholar
• Kim I, Moon SO, Kim SH, et al. Vascular endothelial growth factor expression of intercellular adhesion mole 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem. 2001;276:7614–7620.
   PubMed Web of Science ®Google Scholar
• Min JK, Kim YM, Kim SW, et al. TNF-related activation-induced cytokine enhances leukocyte adhesiveness: Induction of ICAM-1 and VCAM-1 via TNF receptor-associated factor and protein kinase C-dependent NF-kappB activation in endothelial cells. J Immunol. 2005;175:531–540.
   PubMed Web of Science ®Google Scholar
• Mangan SH, Van Campenhout A, Rush C, et al. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin −2. Cardiovasc Res. 2007;76:494–505.
   PubMed Web of Science ®Google Scholar
• Shankar S, Ganapathy S, Srivastava RK. Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Clin Cancer Res. 2008;14:6855–6866.
   PubMed Web of Science ®Google Scholar
• Bolkun L, Lemancewicz D, Piszcz J, et al. Relationship between tumour necrosis factor-related apoptosis inducing ligand (TRAIL) and vascular endothelial growth factor in human multiple myeloma patients. Hematol Oncol. 2015;33:199–205.
   PubMed Web of Science ®Google Scholar
• Bisgin A, Kargi A, Yalcin AD, et al. Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer. BMC Cancer. 2012;12:58.
   PubMed Web of Science ®Google Scholar
• Song K, Chen Y, Göke R, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med. 2000;191:1095–1104.
   PubMed Web of Science ®Google Scholar
• Secchiero P, Corallini F, Di Iasio MG, et al. TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood. 2005;105:3413–3419.
   PubMed Web of Science ®Google Scholar
• Secchiero P, Corallini F, Beltrami AP, et al. An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis. 2010;210:274–277.
   PubMed Web of Science ®Google Scholar
• Bernardi S, Bossi F, Toffoli B, et al. Roles and clinical applications of OPG and TRAIL as biomarkers in cardiovascular disease. Biomed Res Int. 2016;2016:1752854.
   PubMed Web of Science ®Google Scholar
• Kuźniewski M, Fedak D, Dumnicka P, et al. Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure. Adv Med Sci. 2016;61:269–275.
   PubMed Web of Science ®Google Scholar
• Audo R, Daien C, Papon L, et al. Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort. Arthritis Res Ther. 2015;17:193.
   PubMed Web of Science ®Google Scholar
• Castellino G, Corallini F, Bortoluzzi A, et al. The tumour necrosis factor-related apoptosis-inducing ligand-osteoprotegerin system in limited systemic sclerosis: a new disease marker? Rheumatology (Oxford). 2010;49:1173–1176.
   PubMed Web of Science ®Google Scholar
• Hakozaki A, Yoda M, Tohmonda T, et al. Receptor activator of NF-κB (RANK) ligand induces ectodomain shedding of RANK in murine RAW264.7 macrophages. J Immunol. 2010;184:2442–2448.
   PubMed Web of Science ®Google Scholar
• Beuselinck B, Jean-Baptiste J, Couchy G, et al. RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs. Br J Cancer. 2015;113:1313–1322.
   PubMed Web of Science ®Google Scholar
• Kushlinskii NE, Timofeev YS, Solov’ev YN, et al. Components of the RANK/RANKL/OPG system, IL-6, IL-8, IL-16, MMP-2, and calcitonin in the sera of patients with bone tumors. Bull Exp Biol Med. 2014;157:520–523.
   PubMed Web of Science ®Google Scholar
• Santini D, Schiavon G, Vincenzi B, et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One. 2011;6(4):e19234.
   PubMed Web of Science ®Google Scholar
• Park HS, Lee A, Chae BJ, et al. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer. J Surg Oncol. 2014;110:807–812.
   PubMed Web of Science ®Google Scholar
• Pfitzner BM, Branstetter D, Loibl S, et al. RANK expression as a prognostic and predictive marker in breast cancer. Breast Cancer Res Treat. 2014;145:307–315.
   PubMed Web of Science ®Google Scholar
• Cui X, Peng H, Jin J, et al. RANK overexpression as a novel esophageal cancer marker: validated immunohistochemical analysis of two different ethnicities. Int J Clin Exp Pathol. 2015;8:2249–2258.
   PubMed Web of Science ®Google Scholar
• Min JK, Kim YM, Kim YM, et al. Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. J Biol Chem. 2003;278:39548–39557.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Struyf S, Van Damme J, et al. Circulating fibrocytes contribute to the myofibroblast population in proliferative vitreoretinopathy epiretinal membranes. Br J Ophthalmol. 2008;92:699–704.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, De Hertogh G, Van Den Eynde K, et al. Myofibroblasts in proliferative diabetic retinopathy can originate from infiltrating fibrocytes and through endothelial-to-mesenchymal transition (EndoMT). Exp Eye Res. 2015;132:179–189.
   PubMed Web of Science ®Google Scholar
• Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199–210.
   PubMed Web of Science ®Google Scholar
• Wei X, Zhang X, Zuscik MJ, et al. Fibroblasts express RANKL and support osteoclastogenesis in a COX-2-dependent manner after stimulation with titanium particles. J Bone Miner Res. 2005;20:1136–1148.
   PubMed Web of Science ®Google Scholar
• Akram KM, Lomas NJ, Forsyth NR, et al. Alveolar epithelial cells in idiopathic pulmonary fibrosis display upregulation of TRAIL, DR4 and DR5 expression with simultaneous preferential over-expression of pro-apoptotic marker p53. Int J Clin Exp Pathol. 2014;7:552–564.
   PubMed Web of Science ®Google Scholar
• Liu W, Feng W, Wang F, et al. Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease. Exp Mol Pathol. 2008;84:213–217.
   PubMed Web of Science ®Google Scholar
• Collison A, Li J, Pereira De Siqueira A, et al. Tumor necrosis factor-related apoptosis-inducing ligand regulates hallmark features of airways remodeling in allergic airways disease. Am J Respir Cell Mol Biol. 2014;51:86–93.
   PubMed Web of Science ®Google Scholar
• Kahraman A, Barreyro FJ, Bronk SF, et al. TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse. Hepatology. 2008;47:1317–1330.
   PubMed Web of Science ®Google Scholar
• Kaden JJ, Dempfle CE, Kiliç R, et al. Influence of receptor activator of nuclear factor kappa B on human aortic valve myofibroblasts. Exp Mol Pathol. 2005;78:36–40.
   PubMed Web of Science ®Google Scholar
• Collin-Osdoby P, Rothe L, Anderson F, et al. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem. 2001;276:20659–20672.
   PubMed Web of Science ®Google Scholar
• Breuil V, Schmid-Antomarchi H, Schmid-Alliana A, et al. The receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) is a new chemotactic factor for human monocytes. FASEB J. 2003;17:1751–1753.
   PubMed Web of Science ®Google Scholar